



US007893026B2

(12) **United States Patent**
Beyaert et al.

(10) **Patent No.:** **US 7,893,026 B2**
(45) **Date of Patent:** **Feb. 22, 2011**

(54) **TREATMENT OF EGFR-DEPENDENT TUMORS BY ABIN (A20 -BINDING INHIBITOR OF NF KAPPAB)**

(75) Inventors: **Rudi Beyaert**, Zingem (BE); **Hilde Revets**, Meise (BE); **Lieven Huang**, Ledeborg (BE)

(73) Assignees: **VIB VZW**, Zwijnaarde (BE); **Universiteit Gent**, Ghent (BE); **Vrije Universiteit Brussel**, Brussels (BE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 203 days.

(21) Appl. No.: **11/918,559**

(22) PCT Filed: **Apr. 11, 2006**

(86) PCT No.: **PCT/EP2006/061528**

§ 371 (c)(1),
(2), (4) Date: **Jun. 23, 2008**

(87) PCT Pub. No.: **WO2006/108844**

PCT Pub. Date: **Oct. 19, 2006**

(65) **Prior Publication Data**

US 2009/0023650 A1 Jan. 22, 2009

(30) **Foreign Application Priority Data**

Apr. 14, 2005 (EP) 05102967

(51) **Int. Cl.**
A61K 38/00 (2006.01)

(52) **U.S. Cl.** **514/12; 514/21**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,673,897 B1 1/2004 Beyaert et al.
7,094,756 B2 8/2006 Beyaert et al.
7,615,617 B2 * 11/2009 Robinson et al. 530/412

FOREIGN PATENT DOCUMENTS

WO WO 99/57133 11/1999
WO WO 03/000280 A2 1/2003

OTHER PUBLICATIONS

Ibragimova and Eade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198).
Zhang et al (Biochem Biophys Res Comm, 2002, vol. 297, pp. 17-23).
ATCC Website (information for Saosi-2 cells, downloaded from the Web, Oct. 25, 2009).
Abstract of Su (Zhonghua Bing Li Xue Za Zhi, 1995, vol. 24, pp. 93-95).
Heyninck et al., Structure-function analysis of the A20-binding inhibitor of NF-kappaB activation, ABIN-1, FEBS Letters, Feb. 11, 2003, pp. 135-140, vol. 536, No. 1-3, Elsevier, Amsterdam, NL.
Van Huffel et al., Identification of a novel A20-binding inhibitor of nuclear factor-kappa B activation termed ABIN-2, Journal of Biological Chemistry, Aug. 10, 2001, pp. 30216-30223, vol. 276, No. 32.
PCT International Search Report, PCT/EP2006/061528, dated Jul. 18, 2006.

* cited by examiner

Primary Examiner—Karen A Canella
(74) *Attorney, Agent, or Firm*—TraskBritt, P.C.

(57) **ABSTRACT**

The present invention relates to the treatment of epidermal growth factor-family receptor- (ErbB-) dependent tumors. More specifically, the present invention relates to the use of ABIN for the preparation of a medicament to inhibit epidermal growth factor- (EGF-) induced proliferation, and to treat ErbB-dependent tumors.

3 Claims, 4 Drawing Sheets